Now is the time
for pharmaceutical and biotech companies, both large and small, to assess their current sample management strategies to ensure current and future drug
discovery is not jeopardized by sub-optimal management processes or samples or lack of sample data.
On Sept. 19, President Barack Obama announced that the U.S. National Institutes of Health (NIH)
will collaborate with the U.S. Food and Drug Administration (FDA) and the Defense Advanced Research Projects Agency (DARPA) to develop cutting-edge
technologies to predict drug safety.